Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.
Revenue of Longeveron Inc. (LGVN)
Revenue in 2023 (TTM): $709 K
According to Longeveron Inc.'s latest financial reports the company's current revenue (TTM) is $709 K. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Longeveron Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $709 K | $221 K | $-20,060,000 | $-21,413,000 | $-21,413,000 |
| 2022 | $1.22 M | $497 K | $-17,150,000 | $-18,835,000 | $-19,627,000 |
| 2021 | $1.31 M | $590 K | $-16,185,000 | $-17,045,000 | $-17,164,000 |
| 2020 | $5.63 M | $1.83 M | $-2,928,831 | $-3,720,808 | $-3,791,220 |
| 2019 | $5.64 M | $1.75 M | $-2,190,872 | $-2,959,877 | $-2,995,507 |
| 2018 | $2.13 M | $680.65 K | $-5,591,022 | $-6,336,796 | $-6,336,796 |